Developmental and epileptic encephalopathy 108
MONDO:085931417 clinical trials for this condition and its sub-types, 0 tagged with Developmental and epileptic encephalopathy 108 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New epilepsy drug shows promise in long-term safety trial
Disease control CompletedThis study tested the long-term safety of a drug called LP352 (bexicaserin) in 41 people aged 12 to 65 with severe epilepsy syndromes like Dravet or Lennox-Gastaut. Participants took the drug three times daily for up to 52 weeks. The main goal was to check for side effects, while…
Phase 2 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for rare seizure patients: Long-Term drug safety confirmed
Disease control CompletedThis study looked at the long-term safety of a drug called fenfluramine (ZX008) for people with rare seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. A total of 412 participants who had completed earlier studies took the drug and were monitored for side effects…
Phase 3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Routine EEGs may hold hidden clues to childhood epilepsy — a new analysis method is put to the test
Diagnosis CompletedThis study is testing whether a computer tool called BioEP can detect signs of seizure susceptibility in standard EEG recordings from children with epilepsy. Researchers will analyze past EEGs from 530 children aged 2 to 18 who already have an epilepsy diagnosis. The goal is to s…
Sponsor: Neuronostics Ltd • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
New drug candidate TAK-935 tested for Hard-to-Treat epileptic encephalopathies
Symptom relief CompletedResearchers are testing an experimental drug called TAK-935 in adults with developmental and/or epileptic encephalopathies, severe brain conditions that cause frequent seizures and developmental problems. The trial enrolls a small number of participants who continue their regular…
Phase 1/2 • Sponsor: Takeda • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New parent support programme shows promise for families of children with complex needs
Symptom relief CompletedThis pilot study tested a community-based group programme called 'Encompass' for parents of children under 5 with complex neurodisability. Fifteen parents in East London attended ten group sessions over six months. The study aimed to see if the programme was feasible and acceptab…
Sponsor: City, University of London • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC